Developmental Biology Program
The Maria Jasin Lab
Human chromosomes are constantly assaulted by challenges to their integrity as a result of either environmental agents that damage DNA or from normal DNA metabolism. The failure to repair damaged DNA faithfully is ultimately responsible for many human diseases, especially cancer. This laboratory focuses on the repair of 1 particular lesion in DNA, the double-strand break (DSB). DSBs arise from agents, such as ionizing radiation, and can also occur spontaneously during DNA replication. Our emphasis is on repair of DSBs by homologous recombination, with a particular interest in the role of homologous recombination in maintaining genetic stability. Understanding the repair of DSBs is not only important for basic science and health concerns, but also impacts on molecular genetic manipulations of mammalian genomes.
Prakash R, Sandoval T, Morati F, Zagelbaum J, Lim P, White T, Taylor B, Wang R, Desclos E, Sullivan M, Rein H, Bernstein K, Krawczyk P, Gautier J, Modesti M, Vanoli F, and Jasin M. (2021) Distinct pathways of homologous recombination controlled by the SWS1-SWSAP1-SPIDR complex. Nat Commun. doi: 10.1038/s41467-021-24205-6.
Garcin EB, Gon S, Sullivan MR, Brunette GJ, Cian A, Concordet JP, Giovannangeli C, Dirks WG, Eberth S, Bernstein KA, Prakash R, Jasin M, Modesti M. (2019) Differential Requirements for the RAD51 Paralogs in Genome Repair and Maintenance in Human Cells.PLoS Genet. doi: 10.1371/journal.pgen.1008355.
Maria Jasin, PhD
- The Jasin laboratory focuses on double-strand break repair and genomic integrity in mammalian cells and the relationship to tumor suppression.
- PhD, Massachusetts Institute of Technology
- National Academy of Sciences (2015)
- National Academy of Medicine (2016)
- American Academy of Arts and Sciences (2017)
- Basser Global Prize for BRCA Research (2018)
- Shaw Prize in Life Science and Medicine (2019)
- Fellow of the AACR Academy (2020)
- NCI Outstanding Investigator (2020)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Maria Jasin discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.